Fabhalta (iptacopan) - Novartis
Real-World Outcomes of Iptacopan in C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis. (PubMed, Kidney Int Rep) - Oct 16, 2026 - No abstract available 
Journal • Real-world evidence • Complement-mediated Rare Disorders • Glomerulonephritis • Nephrology
http://www.ncbi.nlm.nih.gov/pubmed/42876601
 
; Ana Huerta; Annick Massart; Arenn Jauhal; Ariel Martje Weingarten; Aude Servais; Domenico Giannese; Federica Maritati; Federico Alberici; Franz Schaefer; Giulia Bassanese; Günter Klaus; Jérôme Harambat; Jutta Schröder-Braunstein; Luigi Cirillo; Luis F Quintana Porras; Maddalena Marasà; Maria Cristina Mancuso; Marina Vivarelli; Michaela Geßner; Olivia Boyer; Patricia Hirt-Minkowski; Raquel López Hidalgo; Renato Alberto Sinico; Sebastian Loos; Sigrid Lundberg; Soumita Bagchi
 
Oct 16, 2026
 
Prev Next